- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- ROUNDTABLE: Pharmacy’s future in sync with technology
- UCB seeks approval for Vimpat as stand-alone therapy in adults
- Research: Global epilepsy therapeutics market to reach $4.5B by 2019
NEW YORK — A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.
The Wall Street Journal reported that the Mumbai-based company planned to launch 25 to 30 new generic drugs each year over the next couple of years.
These include contraceptives, as well as antipsychotics and diabetes drugs, according to the article. In September alone, the company received Food and Drug Administration approval for generic versions of Watson's contraceptive NOR-QD (norethindrone) tablets and launched versions of UCB's epilepsy drug Keppra (levetiracetam) and Shionogi's painkiller Ponstel (mefenamic acid).